Mount Sinai researchers identified genes that predict a positive response to selinexor, a multiple myeloma therapy which can have serious side effects for some patients.
Latest results from the phase III IKEMA clinical trial evaluating the monoclonal antibody Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival of 35.7 months (HR: 0.58; 95% CI: 25.8-44.0; n=179), compared to 19.2 months in patients treated with Kd alone (95% CI: 15.8-25.1; n=123), in patients with relapsed multiple myeloma.
FDA has approved Darzalex Faspro (daratumumab + hyaluronidase-fihj) and Kyprolis (carfilzomib) plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
There is an increased risk of second primary malignancies in patients with newly-diagnosed multiple myeloma who received Revlimid (lenalidomide), according to FDA.
Amgen announced positive results from a planned overall survival interim analysis of the Phase III head-to-head ENDEAVOR trial.
Amgen announced that a phase III study evaluating XGEVA (denosumab) versus zoledronic acid met the primary endpoint of non-inferiority (hazard ratio = 0.98, 95 percent CI, 0.85 - 1.14) in delaying the time to first on-study skeletal-related event in patients with multiple myeloma.
Amgen announced top-line results of the phase III CLARION trial, which evaluated an investigational regimen of Kyprolis (carfilzomib), melphalan and prednisone (KMP) versus Velcade() (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem-cell transplant.
A secondary analysis of the phase III ASPIRE trial that showed Kyprolis (carfilzomib) for Injection, in combination with lenalidomide and dexamethasone, improved progression-free survival and overall response rate, compared to lenalidomide and dexamethasone alone, in patients with relapsed multiple myeloma with early disease progression after initial therapy or transplant.
Early findings from a phase III clinical trial showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents.
Panobinostat demonstrated a four-month improvement in median progression-free survival in relapsed and/or refractory multiple myeloma, in combination with bortezomib and dexamethasone, in a phase III trial.
